The purpose of this special series on NPC biomarkers is to present an overview of conventional biomarkers used in NPC detection and monitoring, as well as include several more recent “novel” approaches for study of NPC and EBV for biomarker discovery, which are expected to identify informative biomarkers for its early detection or new biomarkers having prognostic implications. Experts in the field have been invited to provide several papers in this special series of Annals of Nasopharynx Cancer on EBV markers, as well as host biomarkers, for NPC screening, diagnosis, and prognosis and to present new avenues for NPC biomarker discovery. We expect these ongoing concerted efforts for advances in NPC diagnostics will herald in an era for improved early diagnosis and identification of targeted drugs for precision treatment of NPC.
The etiology of nasopharyngeal carcinoma and challenges for its diagnosis and treatment monitoring
EBV and NPC carcinogenesis—an alternative viewpoint
miRNA biomarkers for NPC diagnosis and prognosis
Prognostic value of Epstein-Barr virus biomarkers for nasopharyngeal carcinoma staging and post-treatment surveillance
Epstein-Barr virus-based nasopharyngeal carcinoma population screening
Clinical utility of circulating tumor cells for real-time serial monitoring of nasopharyngeal carcinoma patients
CpG methylation as epigenetic biomarkers for nasopharyngeal carcinoma diagnostics
Classifying the tumor microenvironment to stratify nasopharyngeal carcinoma patients
Plasma Epstein-Barr virus DNA analysis for personalised management of nasopharyngeal carcinoma—current opportunities and challenges
Utility of Epstein-Barr virus (EBV) antibodies as screening markers for nasopharyngeal carcinoma: a narrative review
Disclosure
The series “NPC Biomarkers” was commissioned by the editorial office, Annals of Nasopharynx Cancer without any sponsorship or funding. MLL and LSY served as the unpaid Guest Editors for the series.